Home > Case Analysis & Patient Stories > Others
The patient stories published here are all those subject to the patient's consent.
| Amyotrophic Lateral Sclerosis | Ankylosing Spondylitis | Anti-aging | Ataxia | Autism | Batten Disease | Brain Injury | Cerebral Palsy | Charcot-Marie-Tooth | Chorea | Chronic-Inflammatory-Demyelinating-Polyneuropathy | CIDP | Dementia | Diabetes | Dystonia | Encephalitis/Myelitis Sequela | Encephalomyelitis | Epilepsy | Eye Disorder | Huntington's Disease | Lumbar Plexus Nerve Injuries | Motor Neuron Disease | Moyamoya Disease | Multiple Sclerosis | Multiple System Atrophy | Muscular Diseases | Myasthenia Gravis | Osteogenisis Imperfecta | Others | Parkinson Disease | Periventricular Leukomalacia | Polymyositis | Progressive Bulbar Palsy | Progressive Supranuclear Paralysis | Renal Insufficiency | Rheumatoid Arthritis | Spinal Cord Injury | Spinal Muscular Atrophy | Stroke | Systemic lupus erythematosus | Systemic Sclerosis | Ulcerative Colitis | West Syndrome |

Case Analysis : Huntington's Disease

by Drs. Like Wu, Xiaojuan Wang and Bo Cheng

Huntington's Disease (HD) is caused by a mutated HD gene, which contains many proteins copied by amino acids (glutamino). The normal HD protein contains 10 to 25 pieces of glutamino sequences. However, if there are more than 36 pieces of gultamino in HD protein, the shape of the protein will change, and the newly-changed protein will form a huge cluster in the neurons. This will kill the cells in the brain striatum, which will result in a loss of coordination and dementia.

In recent years, the WSCMC has found through research that if the HD protein changes in the condition of the joint forces of energized amino acids toxicity, then there will be an accumulation of abnormal protein and an α-synuclein abnormal phosphorylation, which consequently causes a disorder in the structure and function of the cells. The WSCMC also discovered that neural stem cells can secrete a kind of histone protein and super family product, including HATs, which can activate the animals' pattern of genes and reduce the accumulation of paraprotein in the nerve corpuscles during animal experimentation. Meanwhile, the organelle and secretion function in neuron-differentiated from neural stem cells, without any problems in the genes, can deal with the issues caused by excitatory amino acid and free radical injuries.

The WSCMC has observed 16 patients suffering from HD after they received the medical treatment of brain cell transplantation therapy. It was found that 13 of them kept a stable condition during a period of five years after the treatment. During animal experimentation, it was also found that fragmentary in terms of production and protein with incomplete functions are connected to the paresthesia of an α-synuclein and the number of inclusion bodies; both of them cause brain cells to die. Neural stem cells can divide into neurons with drug control. With the effect of drug, the neurons will also consume the excess monoamines neurotransmitter, which can protect HD patients' nervous system, improve their quality of life, and extend their days to live. In a word, the stem cell therapy is a new kind of treatment method

Patient Stories:

Case Analysis : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

by Drs.Like Wu, Xiaojuan Wang and Bo Cheng

CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) is a rare peripheral nerve disorder characterized by a gradual weakness in the legs and, to a lesser extent, the arms.
It is the gradual onset, as well as the chronic nature of CIDP, that differentiates it from GBS. Fortunately, CIDP is even rarer than GBS. The estimated amount of new cases is between 1.5 and 3.6 in a million people (compare to GBS: 1-2 in 100,000).

Like GBS, CIDP is caused by damage to the covering of the nerves, called myelin. It can start at any age and can occur in both genders. The weakness occurs over two or more months.

Unlike GBS, CIDP is not self-limiting (with an end to the acute phase). Left untreated, 30% of CIDP patients will reach the point that they are dependent on a wheelchair. Early recognition and treatment can avoid the more serious disabling effects of the disorder.

What causes CIDP?

Current theory holds that the body's immune system which normally protects itself, perceives myelin as a foreign object, and therefore attacks it. What actually starts this process is not clear. Some patients are found to have abnormal proteins in their blood, and these may cause damage.

How is CIDP diagnosed?

Diagnosis of CIDP is based on the symptoms experienced by the patient:
Difficulty walking, which progressively worsens over a few months
Tingling or other abnormal sensations may be experienced
A loss of reflexes, such as twitching in the knee and ankle

Tests may include:

An electrical test, which is a nerve conduction velocity-electromyography study
A spinal tap, to analyze cerebrospinal fluid
Blood and urine tests, including analysis of proteins
There are three general forms of CIDP:
Progressive form - extending over several years
Recurrent form - with multiple episodes that may be separated by months or years
Monophasic form - in which a single episode extends over one to three years without recurrence

How is CIDP treated?

1. Immunotherapy

Prednisone, similar to protective anti-inflammatory corticosteroids that are normally made by the body, may be used as an initial treatment for several reasons. It often improves strength, can conveniently be taken by mouth, and is inexpensive. Side effects can limit its use.

High dose Intravenous Immune Globulins (IVIG), protective blood proteins obtained from healthy volunteers, can be readily be injected into the vein in the patient's arm.
Plasma Exchange (PE), or Plasmapheresis, is when some of the patient's blood is removed and the blood cells returned without the liquid plasma portion of the patient's blood. It may work by removing harmful antibodies contained in the plasma.

2. Treatment for sequela
The chronic process of CIDP causes many patients to have nerve myelin sheath and axon damage, and permanent nerve dysfunction, such as paralysis, speech that is not fluent, dysphagia, urinary disorders, etc.

There have not been any specific treatments available for those with sequela in past few years. The Wu Stem Cell Medical Center (WSCMC) uses stem cells transplantation to treat many cases of CIPD, which has resulted in a clear recovery for many patients.

This medical center found that neural stem cells can be effective in repairing damage in the nerve myelin sheath and axon, and mesenchymal stem cells can be effective for immune regulation, reducing immune system attacks, and preventing recurrence of the disease. Combining these two kinds of stem cells provides a more effective treatment for CIDP patients.

Patient Stories:

Name : Mr.Asqah Sex : Male Nationality : Saudi Arabian Age : 47Y Diagnosis : 1.Ulcerative Colitis(UC) 2. Hyperthyroidism 3. Post cholecystectomy Date of Admission : July 31th, 2017 Treatment hospital/period : Wu Medical Center/21 days Before treatme

Posted at 2018-03-07 by Zhangqi views(0)

Name : Tim Sex : Male Nationality : American Age : 15 months Diagnosis : 1. Leukodystrophy 2. Secondary Epilepsy Date of Admission : March 8th, 2017 Treatment hospital/period : Wu Medical Center/14days Before treatment: The baby was normal when he

Posted at 2017-11-01 by Zhangqi views(6)

Name : Ms.Tantono Sex : Female Nationality : Indonesian Age : 43Y Diagnosis : 1. Lumbar disc herniation 2. Hypertension 1 3. Hyperlipidemia 4. Moderate fatty liver 5. Right kidney stones Date of Admission : December 24th, 2016 Treatment hospital/peri

Posted at 2017-06-01 by Zhangqi views(24)

Name: Gerardo Mazzella Sex: Male Nationality: Australian Age: 39 Diagnosis: Pudendal Nerve Injury Date of Admission : July 28th, 2016 Treatment hospital/period: Wu Medical Center/8days Before treatment: In April 2010, Gerardo felt pain in the right

Posted at 2016-09-29 by Zhangqi views(115)

Name: Jamal Asaad Tunsi Sex: Male Age: 61 Country: Saudi Arabia Diagnosis: 1.Type 2 diabetic peripheral neuropathy;2. Hypertension level 2 high risk group;3. Hyperlipemia;4. Sleep apnea syndrome Date of Admission: 2015-12-17 Treatment hospital/period

Posted at 2016-02-01 by Zhangqi views(216)

Name: Amelia Mahvi Sex: Female Nationality: British Age: 46 years old Diagnosis: 1. Swelling and pain of lower limbs ( peripheral nerve angiopathy), 2. Hyperlipemia Date of Admission : December 29, 2015 Treatment hospital/period : Wu Medical Center/6

Posted at 2016-01-29 by Zhangqi views(117)

Name: Cavallero Baz Constantino Efrain Sex: Male Country: Argentina Age: 5 years Diagnoses: West syndrome, Epilepsy Admission Date: 2013-10-04 Days Admitted to the Hospital: 28 Before treatment: The patient was born when his mother was 38 weeks pregn

Posted at 2014-07-14 by Admin views(110)

Name: Bugshan Salim Ali A Sex: Male Country: Saudi Arabia Age:29 years Diagnoses: 1.Glycogen storage disease, Post tracheotomy 2. Upper respiratory infection Date:June 10, 2014 Days Admitted to Hospital: 13 days Before treatment: The patient suffered

Posted at 2014-07-09 by Admin views(89)
Tel: +86-10-83614932 Fax: +86-10-83614167 Email:  inquiry@wumedicalcenter.com   Contact Us 
Copyright@2013 Runde Healthcare Consulting Limited.